Rohto Pharmaceutical Co.,Ltd.
4527.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | ¥468,332 | ¥512,628 | ¥658,265 |
| - Cash | ¥74,066 | ¥75,839 | ¥77,161 | ¥61,713 |
| + Debt | ¥26,939 | ¥48,882 | ¥50,223 | ¥38,806 |
| Enterprise Value | – | ¥441,375 | ¥485,690 | ¥635,358 |
| Revenue | ¥82,293 | ¥81,964 | ¥82,730 | ¥86,813 |
| % Growth | 0.4% | -0.9% | -4.7% | – |
| Gross Profit | ¥44,830 | ¥45,853 | ¥45,257 | ¥50,489 |
| % Margin | 54.5% | 55.9% | 54.7% | 58.2% |
| EBITDA | ¥12,748 | ¥14,913 | ¥12,558 | ¥16,525 |
| % Margin | 15.5% | 18.2% | 15.2% | 19% |
| Net Income | ¥5,884 | ¥11,769 | ¥6,200 | ¥11,885 |
| % Margin | 7.2% | 14.4% | 7.5% | 13.7% |
| EPS Diluted | 25.01 | 51.39 | 27.04 | 51.95 |
| % Growth | -51.3% | 90.1% | -47.9% | – |
| Operating Cash Flow | – | ¥0 | ¥0 | ¥0 |
| Capital Expenditures | – | ¥0 | ¥0 | ¥0 |
| Free Cash Flow | – | ¥0 | ¥0 | ¥0 |